• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性葡萄膜黑色素瘤患者发生转移扩散的时间相关因素:一项回顾性分析。

Factors associated with time until metastatic spread in patients with primary uveal melanoma: A retrospective analysis.

作者信息

Told Reinhard, Reumueller Adrian, Kreminger Judith, Sacu Stefan, Dunavoelgyi Roman

机构信息

Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.

出版信息

PLoS One. 2025 Aug 19;20(8):e0328360. doi: 10.1371/journal.pone.0328360. eCollection 2025.

DOI:10.1371/journal.pone.0328360
PMID:40828748
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12364332/
Abstract

PURPOSE

To characterize patients with choroidal or ciliary body (CB) melanoma in order to identify factors associated with time until metastasis and further perform a detailed characterization of the factors identified.

METHODS

A mixed model approach was used to identify parameters and patient characteristics associated with time until metastatic event. Consequently, the identified parameters were characterized.

RESULTS

In 383 patients with primary choroidal and CB melanoma, tumor thickness and patient age at diagnosis are associated with time until metastatic event. Mean patient age was 61 ± 13 years, mean choroidal and CB melanoma thickness was 5.1 ± 1.9 mm. Other factors investigated comprising sex, primary tumor width, length, volume, shape, and type of therapy are not associated with time until metastatic event in this patient collective.

CONCLUSION

In conclusion, this study expands the current knowledge on factors associated with metastasis due to primary choroidal or CB melanoma. So far primary choroidal or CB melanoma thickness has been shown to be a risk indicator for metastatic events. Now, we could show that primary choroidal or CB melanoma thickness is also correlated with time until metastatic event. The association can be expressed as: the thicker the primary tumor, the earlier the potential metastatic event. Age may be considered an indirect effect in the model calculated.

摘要

目的

对脉络膜或睫状体(CB)黑色素瘤患者进行特征分析,以确定与转移发生时间相关的因素,并进一步对所确定的因素进行详细特征描述。

方法

采用混合模型方法来确定与转移事件发生时间相关的参数和患者特征。随后,对所确定的参数进行特征描述。

结果

在383例原发性脉络膜和CB黑色素瘤患者中,肿瘤厚度和诊断时的患者年龄与转移事件发生时间相关。患者平均年龄为61±13岁,脉络膜和CB黑色素瘤平均厚度为5.1±1.9毫米。在该患者群体中,所研究的其他因素,包括性别、原发性肿瘤宽度、长度、体积、形状和治疗类型,与转移事件发生时间无关。

结论

总之,本研究扩展了目前关于原发性脉络膜或CB黑色素瘤相关转移因素的知识。到目前为止,原发性脉络膜或CB黑色素瘤厚度已被证明是转移事件的一个风险指标。现在,我们可以表明原发性脉络膜或CB黑色素瘤厚度也与转移事件发生时间相关。这种关联可以表示为:原发性肿瘤越厚,潜在转移事件发生越早。在计算的模型中,年龄可能被视为一种间接影响因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b8/12364332/aaee7aa160be/pone.0328360.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b8/12364332/e17991b072d6/pone.0328360.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b8/12364332/72f0e36bc06a/pone.0328360.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b8/12364332/aaee7aa160be/pone.0328360.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b8/12364332/e17991b072d6/pone.0328360.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b8/12364332/72f0e36bc06a/pone.0328360.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b8/12364332/aaee7aa160be/pone.0328360.g003.jpg

相似文献

1
Factors associated with time until metastatic spread in patients with primary uveal melanoma: A retrospective analysis.原发性葡萄膜黑色素瘤患者发生转移扩散的时间相关因素:一项回顾性分析。
PLoS One. 2025 Aug 19;20(8):e0328360. doi: 10.1371/journal.pone.0328360. eCollection 2025.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
Anterior Approach Total Ankle Arthroplasty with Patient-Specific Cut Guides.使用患者特异性截骨导向器的前路全踝关节置换术。
JBJS Essent Surg Tech. 2025 Aug 15;15(3). doi: 10.2106/JBJS.ST.23.00027. eCollection 2025 Jul-Sep.
5
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
6
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
7
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA?一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
8
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
9
Clinical symptoms, signs and tests for identification of impending and current water-loss dehydration in older people.老年人即将发生和当前失水脱水的识别的临床症状、体征及检查
Cochrane Database Syst Rev. 2015 Apr 30;2015(4):CD009647. doi: 10.1002/14651858.CD009647.pub2.
10
What Are the Complications, Function, and Survival of Tumor-devitalized Autografts Used in Patients With Limb-sparing Surgery for Bone and Soft Tissue Tumors? A Japanese Musculoskeletal Oncology Group Multi-institutional Study.肿瘤灭活自体移植物用于保肢手术治疗骨和软组织肿瘤患者的并发症、功能和生存情况如何?日本肌肉骨骼肿瘤学组多机构研究。
Clin Orthop Relat Res. 2023 Nov 1;481(11):2110-2124. doi: 10.1097/CORR.0000000000002720. Epub 2023 Jun 14.

本文引用的文献

1
Predicting Malignant Transformation of Choroidal Nevi Using Machine Learning.使用机器学习预测脉络膜痣的恶性转化
Res Sq. 2023 Dec 21:rs.3.rs-3778562. doi: 10.21203/rs.3.rs-3778562/v1.
2
Improved Staging of Ciliary Body and Choroidal Melanomas Based on Estimation of Tumor Volume and Competing Risk Analyses.基于肿瘤体积估计和竞争风险分析的睫状体和脉络膜黑色素瘤分期的改进
Ophthalmology. 2024 Apr;131(4):478-491. doi: 10.1016/j.ophtha.2023.10.026. Epub 2023 Oct 29.
3
Current management of uveal melanoma: A review.当前葡萄膜黑色素瘤的治疗管理:综述。
Clin Exp Ophthalmol. 2023 Jul;51(5):484-494. doi: 10.1111/ceo.14214. Epub 2023 Apr 19.
4
Impact of tumour volume and treatment delay on the outcome after linear accelerator-based fractionated stereotactic radiosurgery of uveal melanoma.基于线性加速器的分次立体定向放射外科治疗葡萄膜黑色素瘤的肿瘤体积和治疗延迟对预后的影响。
Br J Ophthalmol. 2024 Feb 21;108(3):457-464. doi: 10.1136/bjo-2022-322750.
5
Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.葡萄膜黑色素瘤的预后生物标志物:现状、最新进展与未来方向
Cancers (Basel). 2021 Dec 25;14(1):96. doi: 10.3390/cancers14010096.
6
Update on uveal melanoma: Translational research from biology to clinical practice (Review).葡萄膜黑色素瘤的研究进展:从基础生物学研究到临床实践的转化(综述)。
Int J Oncol. 2020 Dec;57(6):1262-1279. doi: 10.3892/ijo.2020.5140. Epub 2020 Oct 22.
7
Uveal melanoma.葡萄膜黑素瘤。
Nat Rev Dis Primers. 2020 Apr 9;6(1):24. doi: 10.1038/s41572-020-0158-0.
8
Germline MBD4 Mutations and Predisposition to Uveal Melanoma.胚系 MBD4 突变与葡萄膜黑色素瘤易感性。
J Natl Cancer Inst. 2021 Jan 4;113(1):80-87. doi: 10.1093/jnci/djaa047.
9
Uveal melanoma: Towards a molecular understanding.葡萄膜黑色素瘤:从分子角度理解。
Prog Retin Eye Res. 2020 Mar;75:100800. doi: 10.1016/j.preteyeres.2019.100800. Epub 2019 Sep 26.
10
20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas.质子治疗葡萄膜黑色素瘤后转移潜伏期及随后死亡时间的 20 年评估。
Melanoma Res. 2020 Jun;30(3):272-278. doi: 10.1097/CMR.0000000000000519.